Nanjing Delova Biotechnology Co., Ltd. is a global biotechnology company focused on new drug development in the field of pain relief, aiming to provide long-lasting and effective analgesic medications that are non-opioid based, addressing unmet clinical needs worldwide. With a vision to become a leading global pharmaceutical company in the pain relief sector, Delova Biotechnology utilizes proprietary technologies such as sustained-release injectables, transdermal formulations, and solubility enhancement for difficult-to-dissolve drugs.

Their product pipeline includes treatments for postoperative pain, various neuropathic pain conditions, osteoarthritis, migraines, and stubborn pain like cancer-related pain. With a dedicated research and development team in Nanjing, China, and a subsidiary in California, USA, Delova Biotechnology focuses on innovative drug delivery technologies and emphasizes global market expansion. Their robust portfolio covers multiple drug application pathways, with the first NDA product already in the final stages of commercialization, poised to be the first domestically developed pain medication to enter the US market.

Founded by Dr. Wang Qingsong and Dr. Hu Ning, the company boasts a wealth of experience in pharmaceutical research and development.

Delova Biotechnology is recognized for its innovative approach, strategic partnerships, and commitment to enhancing the quality of human health